To include your compound in the COVID-19 Resource Center, submit it here.

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology.

Swedish Orphan Biovitrum AB (SSE:SOBI) will acquire Dova

Read the full 375 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE